Skip to main content Start main content

研究助理教授

PolyU Scholars Hub

李晶晶博士

助理教授(研究)

BSc (SWJTU), MSc (UM), PhD (HKU)

简历

李晶晶博士分别于西南交通大学与澳门大学获得中药学学士和硕士学位,其后于2020年获香港大学颁授药理学博士学位。加入理大前,他于2020年至2021年期间在香港大学李嘉诚医学院担任博士后研究员。

 

李博士致力于运用各种细胞及动物模型来研究血管生成异常在多种疾病中的病理机制,例如缺血性中风、柏金逊症、阿尔兹海默症和癌症。他同时擅长中药有效活性成分的筛选及其相关药理活性的鉴定。在其研究期间,李博士成功从中药中发现了多种具有治疗前景的生物活性分子,可被用于研发成为治疗心血管疾病、神经退行性疾病和癌症的潜在靶点药物。迄今为止,他已在药理学或综合和补充医学  领域的顶级同行评审期刊上发表逾二十篇科学论文。

 

李博士现任Military Medical Research期刊青年编委,Frontiers in Pharmacology期刊审稿编辑,以及Phytomedicine、Chinese Medicine、Biochemical Pharmacology、Chinese Journal of Natural Medicines等科学期刊的特邀审稿人。他目前的研究侧重于探索血管生成异常化在神经退行性疾病(例如柏金逊症、阿尔兹海默症)发展过程中的调节作用,通过靶向组织内异常血管,调节血管正常化,探索和开发治疗神经系统疾病或癌症的有效策略。

 

学历

  • Bachelor of Science, Southwest Jiaotong University
  • Master of Science in Chinese Medicinal Science, University of Macau
  • Doctor of Philosophy, The University of Hong Kong

研究兴趣

  • 基于中医药治疗神经退行性疾病的策略研究
  • 基于血管正常化疗法治疗脑部相关疾病及癌症的探索研究
  • 补充和替代医学在康复科学领域中的应用

研究成果

    • Wu YH, Li JJ, Zhong XM, Shi JF, Cheng YF, He CL, Li JX, Zou L, Fu CM, Chen MW, Zhang JM, & Gao HL. A pH-sensitive supramolecular nanosystem with chlorin e6 and triptolide co-delivery for chemo-photodynamic combination therapy. Asian Journal of PharmaceuticalSciences (in press). (Co-first author)
    • Liu ZY, Wu XP, Dai K, Li RK, Zhang JM, Sheng DK, Lee SMY, Leung GPH, Zhou GC, & Li JJ (2022). The new andrographolide derivative AGS-30 induces apoptosis in human colon cancer cells by activating a ROS-dependent JNK signalling pathway. Phytomedicine, 94: 153824. (Corresponding author)
    • Li JJ, Li RK, Wu XP, Hoo RLC, Lee SMY, Cheung TMY, Ho BSY, & Leung GPH (2021). Amauroderma rugosum protects PC12 cells against 6-OHDA-induced neurotoxicity through antioxidant and anti-apoptotic effects. Oxidative Medicine and Cellular Longevity, 2021: 6683270.
    • Shi JF, Li JJ, Li JX, Li RK, Wu XP, Gao F, Zou L, Mak WWS, Fu CM, Zhang JM*, & Leung GPH* (2021). Synergistic breast cancer suppression efficacy of doxorubicin by combination with glycyrrhetinic acid as an angiogenesis inhibitor. Phytomedicine, 81: 153408. (Co-first and corresponding author)
    • Luo YY, Li JJ, Hu YC, Gao F, Leung GPH, Geng FN, Fu CM, & Zhang JM (2020). Injectable thermoresponsive nano-hydrogel loading triptolide for the anti-breast cancer enhancement via localized treatment based on “Two Strikes” effects. Acta Pharmaceutica Sinica B, 10(11): 2227-2245. (Co-first author)
    • Li JJ, Li F, Tang F, Zhang JM, Li RK, Sheng DK, Lee SMY, Zhou GC, & Leung GPH (2020). AGS-30, an andrographolide derivative, suppresses tumor angiogenesis and growth in vitro and in vivo. Biochemical Pharmacology, 171: 113694.
    • Li JJ, Tang F, Li RK, Chen ZJ, Lee SMY, Fu CM, Zhang JM, & Leung GPH (2020). Dietary compound glycyrrhetinic acid suppresses tumor angiogenesis and growth by modulating anti-angiogenic and pro-apoptotic pathways in vitro and in vivo. Journal of Nutritional Biochemistry, 77: 108268.
    • Li JJ, Wu YH, Wang D, Zou L, Fu CM, Zhang JM, & Leung GPH (2019). Oridonin synergistically enhances the anti-tumor efficacy of doxorubicin against aggressive breast cancer via pro-apoptotic and anti-angiogenic effects. Pharmacological Research, 146: 104313.
    • Li JJ, Zhang JM, Zou L, Lee SMY, Yang C, Seto SW, & Leung GPH (2017). Pro-angiogenic effects of Ilexsaponin A1 on human umbilical vein endothelial cells in vitro and zebrafish in vivo. Phytomedicine, 36: 229-237.
    • Zhang JM, Li JJ, Shi Z, Yang Y, Xie X, Lee SMY, Wang YT, Leong KW, & Chen MW (2017). pH-sensitive polymeric nanoparticles for co-delivery of doxorubicin and curcumin to treat cancer via enhanced pro-apoptotic and antiangiogenic activities. Acta Biomaterialia, 58: 349-364. (Co-first author)

您的浏览器不是最新版本。如果继续浏览本网站,部分页面未必能够正常运作。

建议您更新至最新版本或选用其他浏览器。您可以按此连结查看其他相容的浏览器。